Compare Brimonidine 0.2% versus Latanoprost 0.005% (Xalatan) in preventing intraocular pressure after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Ardabil city

Authors

  • Habib Ojaghi Department of Medicine, Ardabil University of Medical Science, Ardabil, Iran
  • Rahim Masoumi Department of Medicine, Ardabil University of Medical Science, Ardabil, Iran
  • Solmaz Eskandar-Sani Department of Medicine, Ardabil University of Medical Science, Ardabil, Iran

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20164778

Keywords:

Brimonidine, Latanoprost, Xalatan, YAG laser capsulotomy

Abstract

Background: The transient increase of intraocular pressure (IOP) following neodymium YAG laser capsulotomy can occur in a significant number of patients, which requires prophylactic treatment with IOP reducing drugs, and in some patients, postoperative IOP monitoring. This study was performed to compare the efficacy of brimonidine 0.2% versus latanoprost0.005% (Xalatan) in preventing the IOP elevation after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Alavi Hospital.

Methods: This study was a randomized, double-blind clinical trial that included 100 patients who had developed posterior capsule opacification (PCO) as a result of previous cataract surgery and were candidate for undergoing YAG laser posterior capsulotomy. The patients were randomly divided into two groups of 50 patients. One group received brimonidine 0.2% one hour before surgery, and the other group received Xalatan 0.005% in the night before laser surgery. In both groups the patients' IOP was measured in baseline, 1, 2, 3, 24 hours, 3 days and one week after surgery. The gathered data were analyzed using statistical methods in SPSS.16.

Results: The mean IOP, 1, 2, 3, and 24 hours, 3 days, and one week after surgery didn't show any significant difference between two groups. IOP one hour before surgery changed significantly compared to one hour after surgery and a statistically significant relationship was found between the two groups, though at other times of measurement, the differences were not significant.

Conclusions: Results showed that using Brimonidine 0.2% or Latanoprost 0.005% as prophylactic before YAG laser posterior capsulotomy could be effective in preventing IOP after treatment.

References

Rapuano CJ, Belin MW, Boxer Wachler BS, Donnenfeld ED, Feder RS, Rosenfeld SI, et al. Collagen shrinkage procedures. Refractive Surgery. Section 13. Singapore: American Academy of Ophthalmology (AAO); 2008:150-163.

Riordan-Eva P, FRCS, FRCO phth, Whitcher JP, Albiani DA. Vaughan and Asbury's General Ophthalmology 17th Edition; 2007:178-179.

Fechtner RD, Airaksinen PJ. Efficacy and tolerability of thedorzolamide 2%/ timolol 0.5% combination (COSOPTTM) versus latanoprost 0.005% (XALATANTM) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmologica Scand inavica. 2004;82:42-8.

Yeom HY, Lee JH, Hong YJ, Seong GJ. Brimonidine 0.2% Versus Brimonidine Purite 0.15%: Prophylactic Effect on IOP Elevation After Nd: YAG Laser Posterior Capsulotomy. Journal of Ocular Pharmacology and Therapeutics. 2006;22(3):176-81.

Chen TC. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery. Journal of Cataract and Refractive Surgery. 2005;31:1707-12.

Yuen NSY, Cheung P, Hui SP. Comparing Brimonidine 0.2% to Apraclonidine 1.0% in the privention of intraocular pressure elevation and their pupillary effects following Laser peripheral Iridotomy. Japanese Ophthalmological Society. 2005;49:89-92.

Seong GJ, Lee JH, Lim SJ. Effect of 0.2% Brimonidine in preventing intraocular pressure elevation after Nd: YAG laser posterior capsulotomy. Ophthalmic Surg Laser. 2000;31(4):308-14.

Erdogan H, Toker MI, Arici MK, Topalkara A. Effect of latanoprost 0.005% and Brimonidine 0.2% on intraocular pressure after Phacoemulsification and intraocular Lens implantation surgery. Japanese Ophthalmological Society. 2004;48:598-601.

Novak-Laus K, Masnec-Paskvalin S. Use of antiglaucoma therapy to reduce acute intraocular pressure rise following neodymium: YAG laser iridotomy in angle-closure glaucoma patients. Acta Med Croatica. 2006;60(2):113-6.

Minello, Antonieta, Pereira A. Efficacy of topic ocular hipotensive agents after posterior capsulotomy. Arquivos Brasileiros de Oftalmologia 2008;71(5):706-10.

Nagar M, Ogunyomade A. A randomised prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005;89(11):1413-7.

Liu CJ, Ching-Yu C, Shu-Chiung C, Chiu AW, Chou JCK, Wen-Ming H, et al. Use of latanoprost to reduce acute intraocular pressure rise following neodymium: Yag laser iridotomy. Acta Ophthalmologica Scandinavia; 2002;282-286.

Gartaganis SP, Mela EK, Katsimpris JM. Use of topical brimonidine to prevent intraocular pressure elevations following Nd: YAG-laser posterior capsulotomy. Ophthalmic Surg Lasers. 1999;30(8):647-52.

Stewart WC, Stewart JA. The Safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%. Acta Ophthalmologica Scand inavica. 2004;82:161-5.

Chevrier RL, Assalian A, Duperre J. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Ophthalmic Surg Lasers. 1999,Mar:30(3):199-204.

Unal M, Yucel I, Akar Y. Brinzolamid 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium: YAG laser posterior capsulotomy. Journal of Cataract and Refractive Surgery. 2006;32:1499-502.

Downloads

Published

2016-12-24

How to Cite

Ojaghi, H., Masoumi, R., & Eskandar-Sani, S. (2016). Compare Brimonidine 0.2% versus Latanoprost 0.005% (Xalatan) in preventing intraocular pressure after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Ardabil city. International Journal of Basic & Clinical Pharmacology, 6(1), 189–193. https://doi.org/10.18203/2319-2003.ijbcp20164778

Issue

Section

Original Research Articles